Search
Linagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesClascoterone
go.drugbank.com/drugs/DB12499ApprovedInvestigational[A218771] By competing with androgens for binding to androgen receptors, clascoterone works by blocking the androgen receptor signalling cascades that promote acne pathogenesis, such as sebaceous gland … [L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766]
Categories: Anti-Acne Preparations for Topical Use, Androgen Receptor InhibitorsThrombin alfa
go.drugbank.com/drugs/DB11572ApprovedThrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. Thrombin Alfa is identical in amino acid sequence and structurally similar to naturally occurring human throm...
Guanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnAn antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.
Ethotoin
go.drugbank.com/drugs/DB00754ApprovedEthotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersBenzoctamine
go.drugbank.com/drugs/DB09021ExperimentalIt can also be used as an anxiolytic with the same efficacy as chlordiazepoxide for treating anxiety neurosis. … Benzoctamine is a drug with two main uses. It can be used as a sedative which does not depress the respiratory system, but rather stimulates it.
Nonivamide
go.drugbank.com/drugs/DB11324ApprovedIt is an alkaloid from the Capsicum species. … Nonivamide is an organic compound and a capsaicinoid. It is an amide of pelargonic acid and _vanillylamine_.
Penbutolol
go.drugbank.com/drugs/DB01359ApprovedInvestigationalWithdrawnThis binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. … Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesLumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigational[L23554] Oxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for PH1. … [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme InhibitorsAzintuxizumab vedotin
go.drugbank.com/drugs/DB14847Investigationalinvestigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent